Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
2.500
+0.020 (0.81%)
Mar 6, 2026, 10:50 AM EST - Market open
Annovis Bio Employees
As of December 31, 2024, Annovis Bio had 15 total employees, including 8 full-time and 7 part-time employees. The number of employees decreased by 1 or -6.25% compared to the previous year.
Employees
15
Change (1Y)
-1
Growth (1Y)
-6.25%
Revenue / Employee
n/a
Profits / Employee
-$1,658,963
Market Cap
66.26M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Adicet Bio | 152 |
| XBiotech | 88 |
| BeyondSpring | 40 |
| Mereo BioPharma Group | 36 |
| Q32 Bio | 26 |
| NeurAxis | 21 |
| MediciNova | 13 |
| Cingulate | 13 |
ANVS News
- 3 days ago - Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference - GlobeNewsWire
- 22 days ago - Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease - GlobeNewsWire
- 2 months ago - Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients - GlobeNewsWire
- 2 months ago - Annovis to Host Corporate Update Webinar on January 28, 2026 - GlobeNewsWire
- 3 months ago - Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group - GlobeNewsWire
- 3 months ago - Annovis Announces Two Presentations at the CTAD 2025 Conference - GlobeNewsWire
- 3 months ago - Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study - GlobeNewsWire
- 3 months ago - Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients - Benzinga